Sign in or create an account to add this stock to your watchlist.
About Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900
Debt
Debt-to-Equity RatioN/A
Current Ratio9.16
Quick Ratio9.16
Price-To-Earnings
Trailing P/E Ratio-2.88
Forward P/E Ratio-2.40
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.78 per share
Price / Book1.83
Profitability
EPS (Most Recent Fiscal Year)($1.77)
Net Income$-22,600,000.00
Net MarginsN/A
Return on Equity-461.02%
Return on Assets-58.75%
Miscellaneous
Employees13
Outstanding Shares14,740,000
Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How were Aileron Therapeutics' earnings last quarter?
Aileron Therapeutics (NASDAQ:ALRN) posted its earnings results on Wednesday, May, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.02. View Aileron Therapeutics' Earnings History.
What price target have analysts set for ALRN?
4 analysts have issued 1 year price targets for Aileron Therapeutics' stock. Their predictions range from $19.00 to $20.00. On average, they expect Aileron Therapeutics' share price to reach $19.3333 in the next year. View Analyst Ratings for Aileron Therapeutics.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include Minerva Neurosciences (NERV), Verastem (VSTM), Aquinox Pharmaceuticals (AQXP), Kadmon (KDMN), Cue Biopharma (CUE), Tyme Technologies (TYME), Celyad (CYAD), CTI BioPharma (CTIC), Savara (SVRA), Kindred Biosciences (KIN), Ardelyx (ARDX), MannKind (MNKD), Vital Therapies (VTL), Ocular Therapeutix (OCUL) and AVEO Pharmaceuticals (AVEO).
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Mr. Joseph A. Yanchik III, Founder, Pres, CEO & Director (Age 54)
- Dr. Manuel C. Aivado, Sr. VP, Chief Medical Officer & Chief Scientific Officer (Age 48)
- Mr. Huw M. Nash Ph.D., Co-Founder
- Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 59)
- Ms. Kira A. Nelson CPA, VP of Fin. & Operations (Age 49)
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Has Aileron Therapeutics been receiving favorable news coverage?
News articles about ALRN stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aileron Therapeutics earned a coverage optimism score of 0.19 on Accern's scale. They also assigned news headlines about the company an impact score of 46.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Aileron Therapeutics' major shareholders?
Aileron Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.13%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Cvf, Llc, Lilly Ventures Fund I Llc and Reinhard J Ambros. View Institutional Ownership Trends for Aileron Therapeutics.
Which institutional investors are buying Aileron Therapeutics stock?
ALRN stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Cvf, Llc, Lilly Ventures Fund I Llc and Reinhard J Ambros. View Insider Buying and Selling for Aileron Therapeutics.
How do I buy shares of Aileron Therapeutics?
Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of ALRN stock can currently be purchased for approximately $5.0898.
How big of a company is Aileron Therapeutics?
Aileron Therapeutics has a market capitalization of $75.16 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.
How can I contact Aileron Therapeutics?
Aileron Therapeutics' mailing address is 281 ALBANY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-995-0900 or via email at [email protected]
MarketBeat Community Rating for Aileron Therapeutics (ALRN)
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aileron Therapeutics (NASDAQ:ALRN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Aileron Therapeutics in the last 12 months. Their average twelve-month price target is $19.3333, suggesting that the stock has a possible upside of 279.84%. The high price target for ALRN is $20.00 and the low price target for ALRN is $19.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.3333 | $19.3333 | $19.3333 | $19.3333 |
| Price Target Upside: | 279.84% upside | 57.82% upside | 57.82% upside | 57.82% upside |
Aileron Therapeutics (NASDAQ:ALRN) Consensus Price Target History
Aileron Therapeutics (NASDAQ:ALRN) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Aileron Therapeutics (NASDAQ:ALRN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aileron Therapeutics (NASDAQ ALRN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 6.79%
Aileron Therapeutics (NASDAQ ALRN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2018 | Apple Tree Partners Ii Lp | Major Shareholder | Sell | 107,904 | $6.31 | $680,874.24 | |  |
| 1/9/2018 | Apple Tree Partners Ii Lp | Major Shareholder | Sell | 150,000 | $9.80 | $1,470,000.00 | | |
| 7/5/2017 | Cvf, Llc | Major Shareholder | Buy | 180,000 | $15.00 | $2,700,000.00 | | |
| 7/5/2017 | Lilly Ventures Fund I Llc | Insider | Buy | 250,000 | $15.00 | $3,750,000.00 | | |
| 7/5/2017 | Reinhard J Ambros | Director | Buy | 266,667 | $15.00 | $4,000,005.00 | | |
(Data available from 1/1/2013 forward)
Aileron Therapeutics (NASDAQ ALRN) News Headlines
| Source: |
|
Aileron Therapeutics (NASDAQ:ALRN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aileron Therapeutics (NASDAQ:ALRN) Income Statement, Balance Sheet and Cash Flow Statement
Aileron Therapeutics (NASDAQ ALRN) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
